Transfusion Independence in Lower-Risk, Non-del5(q) Myelodysplastic Syndromes (LR-MDS) Among Patients (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) Transfusions

被引：0
|
作者：
Zeidan, Amer M. [1 ,2 ]
Zhu, Weiwei [2 ]
Wang, Rong [3 ,4 ]
Stahl, Maximilian [1 ,2 ]
Huntington, Scott F. [3 ,5 ]
Giri, Smith [3 ,6 ]
Podoltsev, Nikolai A. [1 ,2 ]
Gore, Steven D. [1 ,3 ]
Ma, Xiaomei [2 ,4 ]
Davidoff, Amy J. [3 ,7 ]
机构：
[1] Yale Sch Med, Sect Hematol, Dept Internal Med, New Haven, CT USA
[2] Yale Sch Med, Yale Canc Outcomes Publ Policy & Effectiveness Re, New Haven, CT USA
[3] Yale Univ, Sch Med, Yale Canc Outcomes Publ Policy & Effectiveness Re, New Haven, CT USA
[4] Yale Univ, Yale Sch Publ Hlth, Dept Chron Dis, New Haven, CT USA
[5] Yale Univ, Sch Med, Dept Internal Med, Sect Hematol, New Haven, CT 06510 USA
[6] Yale Univ, Sch Med, Sect Hematol, New Haven, CT USA
[7] Yale Univ, Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-116497
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
838
引用
收藏
页数：3
相关论文
共 49 条
  • [31] Efficacy and Safety of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS): Full Analysis of the COMMANDS Trial
    Garcia-Manero, Guillermo
    Platzbecker, Uwe
    Santini, Valeria
    Zeidan, Amer M.
    Fenaux, Pierre
    Komrokji, Rami S.
    Shortt, Jake
    Valcarcel, David
    Jonasova, Anna
    Dimicoli-Salazar, Sophie
    Tiong, Ing Soo
    Lin, Chien-Chin
    Li, Jiahui
    Zhang, Jennie
    Giuseppi, Ana Carolina
    Kreitz, Sandra
    Pozharskaya, Veronika
    Keeperman, Karen L.
    Rose, Shelonitda
    Prebet, Thomas
    Degulys, Andrius
    Paolini, Stefania
    Cluzeau, Thomas
    Della Porta, Matteo Giovanni
    BLOOD, 2023, 142
  • [32] Impact of Somatic Gene Mutations on Response to Lenalidomide (LEN) in IPSS Lower-Risk Myelodysplastic Syndromes (MDS) Patients (Pts) without Del(5q) and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents (ESAs)
    Santini, Valeria
    Fenaux, Pierre
    Giagounidis, Aristoteles
    Platzbecker, Uwe
    List, Alan F.
    Zhong, Jianhua
    Wu, Chengqing
    Mavrommatis, Konstantinos
    Beach, C. L.
    Hoenekopp, Albert
    MacBeth, Kyle J.
    BLOOD, 2016, 128 (22)
  • [33] Treatment With Imetelstat Provides Durable Transfusion Independence in Heavily Transfused Non-Del(5q) Lower-Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 12 - 14
  • [34] Efficacy and safety of luspatercept versus epoetin alfa (EA) in erythropoiesis-stimulating agent (ESA)-naive patients (pts) with transfusion-dependent (TD) lower-risk myelodysplastic syndromes (LR-MDS): full analysis of the COMMANDS trial
    Platzbecker, Uwe
    Garcia-Manero, Guillermo
    Santini, Valeria
    Zeidan, Amer M.
    Fenaux, Pierre
    Komrokji, Rami S.
    Shortt, Jake
    Valcarcel, David
    Jonasova, Anna
    Dimicoli-Salazar, Sophie
    Tiong, Ing Soo
    Lin, Chien-Chin
    Li, Jiahui
    Zhang, Jennie
    Giuseppi, Ana Carolina
    Kreitz, Sandra
    Pozharskaya, Veronika
    Keeperman, Karen L.
    Rose, Shelonitda
    Prebet, Thomas
    Degulys, Andrius
    Paolini, Stefania
    Cluzeau, Thomas
    Porta, Matteo Giovanni
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 243 - 243
  • [35] DIRECT COST OF MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A DELETION 5Q CYTOCENETIC ABNORMALITY (DEL5Q MDS) IN PATIENTS WHO ARE RED BLOOD CELL TRANSFUSION DEPENDENT IN MEXICO
    Reyes Lopez, A.
    Lemus Villafuerte, F.
    Hernandez Rivera, C.
    Pacheco Alvarez, I
    Lemus-Carmona, E. A.
    VALUE IN HEALTH, 2015, 18 (07) : A665 - A665
  • [36] Safety of Lenalidomide (LEN) 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS): Pooled Analysis of Treatment-Emergent Adverse Events (TEAEs)
    Almeida, Antonio
    Santini, Valeria
    Croepper, Stefanie
    Jonasova, Anna
    Vey, Norbert
    Giagounidis, Aristoteles
    Hellstrom-Lindberg, Eva
    Mufti, Ghulam J.
    Sanz, Guillermo
    Skikne, Barry
    Hoenekopp, Albert
    Seguy, Francis
    Zhong, Jianhua
    Fenaux, Pierre
    BLOOD, 2015, 126 (23)
  • [37] UPDATE ON SAFETY AND LONG-TERM OUTCOMES IN LENALIDOMIDE (LEN)-TREATED PATIENTS WITH RED BLOOD CELL (RBC) TRANSFUSION-DEPENDENT LOW-/INT-1-RISK MYELODYSPLASTIC SYNDROMES (MDS) AND DEL(5Q)
    Hellstrom-Lindberg, E.
    Giagounidis, A.
    Selleslag, D.
    Mittelman, M.
    Muus, P.
    Benettaib, B.
    Fu, T.
    Fenaux, P.
    HAEMATOLOGICA, 2012, 97 : 358 - 359
  • [38] Association Of Cytogenetic Response (CyR) With RBC Transfusion-Independence (RBC-TI) and L-Free Survival In Lenalidomide (LEN)-Treated Patients (Pts) With IPSS Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) With Del(5q)
    Sekeres, Mikkael A.
    Swern, Arlene S.
    Giagounidis, Aristoteles
    List, Alan
    Schlegelberger, Brigitte
    Fenaux, Pierre
    Shiansong, Jack
    Sugrue, Mary M.
    BLOOD, 2013, 122 (21)
  • [39] The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study
    Santini, Valeria
    Almeida, Antonio
    Giagounidis, Aristoteles
    Platzbecker, Uwe
    Buckstein, Rena
    Beach, C. L.
    Guo, Shien
    Altincatal, Arman
    Wu, Chengqing
    Fenaux, Pierre
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (02): : 136 - +
  • [40] MDS-005 STUDY: EFFECT OF BASELINE ENDOGENOUS ERYTHROPOIETIN ON RBC TRANSFUSION INDEPENDENCE IN LENALIDOMIDE-TREATED PATIENTS WITH LOW OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES WITHOUT DEL(5Q)
    Santini, V.
    Li, J. S.
    Swern, A. S.
    Almeida, A.
    Giagounidis, A.
    Fu, T.
    Hoenekopp, A.
    Beach, C.
    Skikne, B.
    Fenaux, P.
    HAEMATOLOGICA, 2015, 100 : 69 - 69
12345